CD4+ T cell–mediated HLA class II cross-restriction in HIV controllers

The structural basis of HIV-Gag recognition by class II–restricted T cell receptors in spontaneous controllers. Spontaneous HIV controllers A small number of HIV-infected individuals (<1%) can spontaneously control HIV in the absence of antiretroviral therapy. Because CD4+ and CD8+ T cell responses are thought to contribute to protection, HIV-responsive T cell receptors (TCRs) from these individuals are of considerable interest. Galperin et al. have examined how three public class II–restricted TCRs—F24, F25, and F5—documented in spontaneous controllers are capable of binding a Gag peptide, Gag 293–312, in the context of multiple HLA-DR molecules. By solving the structures of multiple TCR–peptide–HLA-DR complexes, the authors report that the ability of these TCRs to recognize this Gag peptide in the context of multiple HLA-DR allomorphs is shaped by extensive contacts between these TCRs and the peptide itself. Rare individuals, termed HIV controllers, spontaneously control HIV infection by mounting efficient T cell responses against the virus. Protective CD4+ T cell responses from HIV controllers involve high-affinity public T cell receptors (TCRs) recognizing an immunodominant capsid epitope (Gag293) presented by a remarkably broad array of human leukocyte antigen (HLA) class II molecules. Here, we determine the structures of a prototypical public TCR bound to HLA-DR1, HLA-DR11, and HLA-DR15 molecules presenting the Gag293 epitope. TCR recognition was driven by contacts with the Gag293 epitope, a feature that underpinned the extensive HLA cross-restriction. These high-affinity TCRs promoted mature immunological synapse formation and cytotoxic capacity in both CD4+ and CD8+ T cells. The public TCRs suppressed HIV replication in multiple genetic backgrounds ex vivo, emphasizing the functional advantage conferred by broad HLA class II cross-restriction.

[1]  M. A. van der Hoorn,et al.  Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. , 2003, Blood.

[2]  Victor Appay,et al.  A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells. , 2013, Immunity.

[3]  O. Lambotte,et al.  HIV Controller CD4+ T Cells Respond to Minimal Amounts of Gag Antigen Due to High TCR Avidity , 2010, PLoS pathogens.

[4]  E. Rosenberg,et al.  Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction , 2007, Nature Immunology.

[5]  Mark M. Davis,et al.  T-Cell Receptor (TCR) Clonotype-Specific Differences in Inhibitory Activity of HIV-1 Cytotoxic T-Cell Clones Is Not Mediated by TCR Alone , 2017, Journal of Virology.

[6]  P. Gregersen,et al.  Analysis of the molecular specificities of anti-class II monoclonal antibodies by using L cell transfectants expressing HLA class II molecules. , 1988, Journal of immunology.

[7]  James McCluskey,et al.  T cell antigen receptor recognition of antigen-presenting molecules. , 2015, Annual review of immunology.

[8]  A. Sette,et al.  Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. , 2001, The Journal of clinical investigation.

[9]  David A. Price,et al.  Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover , 2007, The Journal of experimental medicine.

[10]  Pierre Lechat,et al.  Public T cell receptors confer high-avidity CD4 responses to HIV controllers. , 2016, The Journal of clinical investigation.

[11]  J. Goedert,et al.  Killer cell immunoglobulin – like receptor 3 DL 1 variation modifies HLA-B * 57 protection against HIV-1 , 2018 .

[12]  Jeffrey N. Martin,et al.  HIV Controllers with HLA-DRB1*13 and HLA-DQB1*06 Alleles Have Strong, Polyfunctional Mucosal CD4+ T-Cell Responses , 2010, Journal of Virology.

[13]  J. Goedert,et al.  Killer cell immunoglobulin–like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1 , 2018, The Journal of clinical investigation.

[14]  P. Vidalain,et al.  Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells , 2000, Gene Therapy.

[15]  Todd M. Allen,et al.  Antiviral CD8+ T Cells Restricted by Human Leukocyte Antigen Class II Exist during Natural HIV Infection and Exhibit Clonal Expansion , 2016, Immunity.

[16]  M. Carrington,et al.  Association of HLA-DRB1-restricted CD4+ T cell responses with HIV immune control , 2013, Nature Medicine.

[17]  Asier Sáez-Cirión,et al.  HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype , 2007, Proceedings of the National Academy of Sciences.

[18]  O. Lambotte,et al.  HIV Controllers Maintain a Population of Highly Efficient Th1 Effector Cells in Contrast to Patients Treated in the Long Term , 2012, Journal of Virology.

[19]  Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. , 2009, Blood.

[20]  Colin R. F. Monks,et al.  Three-dimensional segregation of supramolecular activation clusters in T cells , 1998, Nature.

[21]  Michael Loran Dustin,et al.  Signaling and Polarized Communication Across the T Cell Immunological Synapse. , 2016, Annual review of cell and developmental biology.

[22]  D. Costagliola,et al.  Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV , 2009, AIDS.

[23]  S. Lewin,et al.  HIV cure and eradication: how will we get from the laboratory to effective clinical trials? , 2011, AIDS.

[24]  E. Rosenberg,et al.  HIV-Specific Cytolytic CD4 T Cell Responses During Acute HIV Infection Predict Disease Outcome , 2012, Science Translational Medicine.

[25]  D. Watkins,et al.  Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection , 2009, Proceedings of the National Academy of Sciences.

[26]  M. Lederman,et al.  Towards an HIV cure: a global scientific strategy , 2012, Nature Reviews Immunology.

[27]  Todd M. Allen,et al.  TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection , 2012, Nature Immunology.

[28]  Todd M. Allen,et al.  Effects of thymic selection of the T cell repertoire on HLA-class I associated control of HIV infection , 2010, Nature.

[29]  Z. Grossman,et al.  HIV-1 Viremia Prevents the Establishment of Interleukin 2–producing HIV-specific Memory CD4+ T Cells Endowed with Proliferative Capacity , 2003, The Journal of experimental medicine.

[30]  Brigitte Autran,et al.  Escape from highly effective public CD8+ T-cell clonotypes by HIV. , 2011, Blood.

[31]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[32]  M. Robb,et al.  Cooperativity of HIV-Specific Cytolytic CD4 T Cells and CD8 T Cells in Control of HIV Viremia , 2015, Journal of Virology.

[33]  J. Goedert,et al.  Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells , 2018, Science.